High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study

被引：22
|
作者：
Reyes, Henry D. [1 ]
Miecznikowski, Jeffrey [2 ]
Gonzalez-Bosquet, Jesus [1 ]
Devor, Eric J. [1 ]
Zhang, Yuping [1 ]
Thiel, Kristina W. [1 ]
Samuelson, Megan I. [3 ]
McDonald, Megan [1 ]
Stephan, Jean-Marie [1 ]
Hanjani, Parviz [4 ]
Guntupalli, Saketh [5 ]
Tewari, Krishnansu S. [6 ]
Backes, Floor [7 ]
Ramirez, Nilsa [8 ]
Fleming, Gini F. [9 ]
Filiaci, Virginia [10 ]
Birrer, Michael J. [11 ]
Leslie, Kimberly K. [1 ]
机构：
[1] Univ Iowa, Holden Comprehens Canc Ctr, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[2] SUNY Univ Buffalo, Dept Biostat, Buffalo, NY USA
[3] Univ Iowa, Holden Comprehens Canc Ctr, Dept Pathol, Iowa City, IA 52242 USA
[4] Abington Mem Hosp, Dept Gynecol Oncol, Hanjani Inst Gynecol Oncol, Abington, PA 19001 USA
[5] Univ Colorado Denver, Dept Obstet & Gynecol, Aurora, CO USA
[6] Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, Orange, CA USA
[7] Ohio State Univ, Med Ctr, Dept Div Obstet & Gynecol, Columbus, OH 43210 USA
[8] Nationwide Childrens Hosp, Res Inst, Dept Pathol, Columbus, OH USA
[9] Univ Chicago, Sect Med Oncol, Chicago, IL 60637 USA
[10] Roswell Pk Canc Inst, NRG Oncol, Gynecol Oncol Grp, Biostat & Data Ctr, Buffalo, NY 14263 USA
[11] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA
来源：
GYNECOLOGIC ONCOLOGY | 2017年 / 146卷 / 02期
关键词：
PHASE-III TRIAL; OVEREXPRESSION; CARCINOMA; CHEMOTHERAPY; PROGNOSIS; PROLIFERATION; METASTASIS; MIGRATION; SUGGESTS; TUMORS;
D O I：
10.1016/j.ygyno.2017.05.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective. Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing
引用
收藏
页码：247 / 253
页数：7
相关论文
共 50 条
  • [1] FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Jeske, Yvette W.
    Ali, Shamshad
    Byron, Sara A.
    Gao, Feng
    Mannel, Robert S.
    Ghebre, Rahel G.
    DiSilvestro, Paul A.
    Lele, Shashikant B.
    Pearl, Michael L.
    Schmidt, Amy P.
    Lankes, Heather A.
    Ramirez, Nilsa C.
    Rasty, Golnar
    Powell, Matthew
    Goodfellow, Paul J.
    Pollock, Pamela M.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 366 - 373
  • [2] Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
    McMeekin, D. Scott
    Tritchler, David L.
    Cohn, David E.
    Mutch, David G.
    Lankes, Heather A.
    Geller, Melissa A.
    Powell, Matthew A.
    Backes, Floor J.
    Landrum, Lisa M.
    Zaino, Richard
    Broaddus, Russell D.
    Ramirez, Nilsa
    Gao, Feng
    Ali, Shamshad
    Darcy, Kathleen M.
    Pearl, Michael L.
    DiSilvestro, Paul A.
    Lele, Shashikant B.
    Goodfellow, Paul J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 3062 - +
  • [3] The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
    Rocconi, Rodney P.
    Lankes, Heather A.
    Brady, William E.
    Goodfellow, Paul J.
    Ramirez, Nilsa C.
    Alvarez, Ronald D.
    Creasman, William
    Fernandez, Jose R.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 264 - 269
  • [4] Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Zighelboim, Israel
    Ali, Shamshad
    Lankes, Heather A.
    Backes, Floor
    Moore, Kathleen
    Mutch, David
    Robison, Katina
    Behbakht, Kian
    Waggoner, Steven
    Ghebre, Rahel G.
    Pearl, Michael
    Ramirez, Nilsa C.
    Goodfellow, Paul
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 614 - 619
  • [5] Receipt of adjuvant endometrial cancer treatment updates according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
    Felix, Ashley S.
    Cohn, David E.
    Brasky, Theodore M.
    Zaino, Richard
    Park, Kay
    Mutch, David G.
    Creasman, William T.
    Thaker, Premal H.
    Walker, Joan L.
    Moore, Richard G.
    Lele, Shashikant B.
    Guntupalli, Saketh R.
    Downs, Levi S.
    Nagel, Christa, I
    Boggess, John F.
    Pearl, Michael L.
    Ioffe, Olga B.
    Randall, Marcus E.
    Brinton, Louise A.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (05) : 459.e1 - 459.e11
  • [6] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Bender, David
    Sill, Michael W.
    Lankes, Heather A.
    Reyes, Henry D.
    Darus, Christopher J.
    Delmore, James E.
    Rotmensch, Jacob
    Gray, Heidi J.
    Mannel, Robert S.
    Schilder, Jeanne M.
    Hunter, Mark I.
    McCourt, Carolyn K.
    Samuelson, Megan I.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
  • [7] Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
    Felix, A. S.
    Brasky, T. M.
    Cohn, D. E.
    Mutch, D. G.
    Creasman, W. T.
    Thaker, P. H.
    Walker, J. L.
    Moore, R. G.
    Lele, S. B.
    Guntupalli, S. R.
    Downs, L. S.
    Nagel, Ci
    Boggess, J. F.
    Pearl, M. L.
    Ioffe, O. B.
    Deng, W.
    Miller, D. S.
    Brinton, L. A.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (06) : 1102 - 1115
  • [8] Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P
    Levine, D. A.
    Dizon, D. S.
    Carlson, J. W.
    Filiaci, V. L.
    Powell, M. A.
    Secord, A. A.
    Tewari, K. S.
    Bender, D. P.
    O'Malley, D. M.
    Stuckey, A. R.
    Moore, K. N.
    Dewdney, S. B.
    Gao, J.
    Dao, F.
    Soslow, R. A.
    Lankes, H. A.
    Aghajanian, C. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 12 - 13
  • [9] Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study
    Casablanca, Yovanni
    Wang, Guisong
    Lankes, Heather A.
    Tian, Chunqiao
    Bateman, Nicholas W.
    Miller, Caela R.
    Chappell, Nicole P.
    Havrilesky, Laura J.
    Wallace, Amy Hooks
    Ramirez, Nilsa C.
    Miller, David S.
    Oliver, Julie
    Mitchell, Dave
    Litzi, Tracy
    Blanton, Brian E.
    Lowery, William J.
    Risinger, John, I
    Hamilton, Chad A.
    Phippen, Neil T.
    Conrads, Thomas P.
    Mutch, David
    Moxley, Katherine
    Lee, Roger B.
    Backes, Floor
    Birrer, Michael J.
    Darcy, Kathleen M.
    Maxwell, George Larry
    CANCERS, 2022, 14 (17)
  • [10] Chemotherapy toxicity and quality of life in older women with advanced or recurrent endometrial cancer: An NRG Oncology - Gynecologic Oncology Group ancillary study
    Ko, E. M.
    Java, J.
    Van Le, L.
    Schmitz, K.
    Randall, M. E.
    Bloss, J. D.
    Fleming, G.
    Moore, D. H.
    Monk, B. J.
    Muss, H. B.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 32 - 32
12345